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Abstract: Induction chemotherapy (ICT) is a controversial treatment for 
head and neck squamous cell carcinomas (HNSCC).   Despite numerous 
randomized controlled trials (RCTs), a majority do not have enough 
statistical power alone to conclude ICT's treatment value among oral 
squamous carcinoma patients (OSCC) since many addressed HNSCC as one 
entity instead of by specific subtypes.  By performing a systematic 
review and cumulative meta-analysis, we aim to determine the benefits of 
ICT in OSCC therapy.  A literature search identified for RCTs comparing 
OSCC patients who received ICT against those without.  Log-hazard ratio, 
and relative risk were used for comparison.  Heterogeneity was determined 
using the I2 statistic package.  The primary endpoint was overall 
survival (OS), followed by disease-free survival (DFS), locoregional 
recurrence (LRR) and distant metastasis (DM) as secondary endpoints.  
RESULTS:  27 randomized trials were included for analysis (n= 2872 
patients).  The shortest median follow-up was 15 months whereas the 
longest was 11.5 years.   ICT does not improve OS (HR = 0.947, 95% CI 
0.85-1.05, p= 0.318), DFS (RR= 1.05, 95% CI 0.92-1.21, p= 0.462) and DM 
(RR= 0.626, CI 95% 0.361-1.086, p= 0.096) compared to locoregional 
treatment alone.  However, there was a significant improvement to LRR 
(RR= 0.778, 95% CI 0.622-0.972, p= 0.027).  There is no evidence ICT 
improves survival outcomes for OSCC patients. However, ICT reduces 






 ICT provides no additional benefit to OS, DFS, and DM endpoints for OSCC 
survival  
 LRR may be improved with the addition of ICT in OSCC treatment  
 A cumulative meta-analysis is an effective tool to visualize and identify survival 
trends over time and should be considered for use in conjunction with the 
traditional meta-analysis format 
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Abstract 
 Induction chemotherapy (ICT) is a controversial treatment for head and neck squamous 
cell carcinomas (HNSCC).   Despite numerous randomized controlled trials (RCTs), a 
majority do not have enough statistical power alone to conclude ICT’s treatment value 
among oral squamous carcinoma patients (OSCC) since many addressed HNSCC as 
one entity instead of by specific subtypes.  By performing a systematic review and 
cumulative meta-analysis, we aim to determine the benefits of ICT in OSCC therapy.  A 
literature search identified for RCTs comparing OSCC patients who received ICT 
against those without.  Log-hazard ratio, and relative risk were used for comparison.  
Heterogeneity was determined using the I2 statistic package.  The primary endpoint was 
overall survival (OS), followed by disease-free survival (DFS), locoregional recurrence 
(LRR) and distant metastasis (DM) as secondary endpoints.  RESULTS:  27 
randomized trials were included for analysis (n= 2872 patients).  The shortest median 
follow-up was 15 months whereas the longest was 11.5 years.   ICT does not improve 
OS (HR = 0.947, 95% CI 0.85-1.05, p= 0.318), DFS (RR= 1.05, 95% CI 0.92-1.21, p= 
0.462) and DM (RR= 0.626, CI 95% 0.361-1.086, p= 0.096) compared to locoregional 
treatment alone.  However, there was a significant improvement to LRR (RR= 0.778, 
95% CI 0.622-0.972, p= 0.027).  There is no evidence ICT improves survival outcomes 
for OSCC patients. However, ICT reduces locoregional recurrence of OSCC, which may 
need further verification.   
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INTRODUCTION  
Squamous cell carcinomas of the oral cavity (OSCC) is the 10th most common 
malignancy worldwide1.  The aggressive nature of advanced OSCC usually indicates a 
poor prognosis, requiring a multi-nodal treatment strategy of chemotherapy, surgery and 
radiotherapy.   Despite advances in treatment options, locoregional recurrence (LRR) 
and distant metastasis (DM) rates remain high at around 30% and 25% respectively 
with minimal improvement to 5-year survival rates as they remain approximately at 
50%1,2.   While guidelines from the National Comprehensive Cancer Network 
recommend surgical excision followed by concurrent single–agent cisplatin chemo-
radiotherapy in T3 or T4 lesions demonstrating adverse features of extrascapular 
spread and/or positive margins3, the most optimal approach for managing advanced 
OSCC is still unclear.      
The introduction of induction chemotherapy (ICT) showed promise for improving 
survival in advanced head and neck cancers from the high response rates to ICT 
demonstrated by trials in the 1990s4,5.   It was hypothesized ICT would increase overall 
survival (OS), disease-free survival (DFS) and progression free survival by improving 
distant control6.   Shrinking tumor volume prior to definitive treatment with ICT could 
enhance radiotherapy feasibility and tolerability whilst reducing the disfiguring effects of 
surgery and radiation6.   
Multiple randomized trials (RCT) have evaluated OSCC response to ICT.  Integration of 
data from independent studies is performed through meta-analysis where data from 
individual trials are pooled simultaneously to provide a summary for evidence-based 
care.  Despite its perceived advantages, multiple meta-analyses did not find significant 
improvements to OS when ICT was added to treatment7-12.  However, interest in ICT 
has been renewed by the improved efficacy to survival using a taxane regimen, and 
improved loco-regional control by concomitant chemo-radiotherapy (CCRT)10.     
Complementary to the ‘traditional’ method of meta-analysis, the ‘cumulative’ meta-
analysis approach creates repeated poolings as each new study is added13.  The overall 
analysis becomes a continuum of accumulating data, offering a visual depiction of 
trends and when significance, or if any significance of an endpoint had been achieved 
over the years for safety and ethical monitoring.   
Due to the enduring uncertainty of ICT’s role and the continued publications of RCTs 
investigating ICT in OSCC treatment, this paper aims to summarize the effect of ICT in 
OSCC treatment by performing an updated systematic review and cumulative meta-
analysis from the earliest to most recent published studies.     
 
METHODS AND MATERIALS:  
This systematic review followed the Cochrane Collaboration Handbook of Interventions 
Systematic Reviews and the PRISMA statement checklist and flowchart.  Cumulative 
meta-analysis was performed where studies were added in order of date to summarize 
the evaluated endpoints.   
Search Methods 
A sensitive search protocol was developed to retrieve RCTs published in peer-reviewed 
journals from 1980 to March 2016 using MEDLINE via Pubmed (1970–March 2016), 
EMBASE via Ovid (1980–March 2016), The Cochrane Central Register of Controlled 
Trials (CENTRAL) (1970- March 2016), and Web of Science (1956- 2016).    
Search queries included MeSH terms for “Head and Neck Neoplasms”, “mouth 
neoplasms”, “gingival neoplasms”, “palatal neoplasms”, “tongue neoplasms”, “lip 
neoplasms”, “mouth squamous cell carcinoma”, “induction chemotherapy”, “neoadjuvant 
therapy”, and “anti-neoplastic drugs” in combination with free text phrases such as 
“primary chemotherapy”, “initial chemotherapy” and “oral cavity”.  The syntax input was 
revised for each database.    The Cochrane Highly Sensitive Search Strategy for 
identifying randomized trials in MEDLINE: sensitivity maximizing version (revision): 
PubMed Format was applied for the MEDLINE search whilst the EMBASE search 
strategy was combined with the Cochrane Oral Health Groups’ RCT filter to maximize 
retrieving clinical trial articles.    
To identify for any current ongoing or missed trials from the search queries, 
ClinicalTrials.gov and manual searches of reference lists from relevant systematic 
reviews and meta-analyses, and abstract conferences were screened.   No language 
restrictions were imposed.   
Study Selection Criteria  
Studies included had the following characteristics:  
1. Participants: Patients diagnosed only with previously untreated primary OSCC 
with or without nodal involvement or metastasis.   
2. Types of interventions: Patients randomized to either receive or not receive 
ICT with their definitive treatment.  All types of chemotherapeutic agents and 
routes of administration were included.  Definitive treatment describes treatment 
best suited for the patient at the time after all other choices have been 
considered to eliminate the disease.   This could be surgery alone, radiotherapy 
alone, concurrent chemo-radiotherapy alone, or any of the three in combination.   
3. Outcomes:  Primary outcome is to assess whether ICT improves OS.  
Secondary outcomes will evaluate DFS, LRR, and DM.  If a study only provided 
figures on secondary outcomes, it was still included only into relevant sections of 
this analysis.   
4. Studies:  RCTs  
Studies were excluded if:  
1. Trial was not a RCT 
2. Patients had received prior intervention 
3. Secondary or recurrent OSCC  
4. Other histological types of oral cancer   
5. ICT was not compared to locoregional treatment alone   
6. Radiotherapy was included in the induction protocol  
Study selection and data extraction  
Two authors independently reviewed for studies that met the eligibility criteria.   An initial 
screen was performed through reading the title/abstract.   If the title/abstract was 
unclear whether a study fulfilled the inclusion criteria, a full article was obtained.  
Characteristics of excluded studies were documented and counterchecked by each 
author.  Any disagreements or inconsistencies were resolved amongst group discussion.      
The corresponding author was contacted for the availability of individual data on OSCC 
patients in trials which included general head and neck cancer patients, or if 
clarifications were required.  Studies comparing multiple ICT regiments against one 
control had the interventions combined into a large cohort to avoid inflating sample size 
data from double-counting the control groups.    
Assessment of Bias  
Following the Cochrane Collaboration’s Tool (Cochrane Handbook version 5.1.0), a risk 
of bias assessment was conducted from the following domains: sequence generation, 
allocation concealment, complete outcome data, selective outcome reporting and other 
potential bias.  Outcome data was considered complete if less than 20% of patients 
randomized were excluded from the trial data with appropriate reasoning described.   
Blinding of participants, personnel and outcome assessors was not measured due to 
the difficulty and unethicality of performing a double-blinded trial under such 
circumstances.   The absence of blinding should not affect OS statistics but may 
influence DFS, LRR and DM reporting.    If it was difficult to interpret bias risk from the 
published article, the study authors were contacted for clarification.  An “unclear risk of 
bias” would be concluded if the author could not be reached and if the available 
information was insufficient for a proper bias assessment.   The Beggs and Egger’s 
regression test would also be used for OS, and for any endpoints that achieved 
significance as a supplement to compensate for studies categorized with an “unclear 
risk” from the Cochrane risk of bias assessment tool.   
Data analysis 
OS was expressed as log hazard ratios (HR).  If HR were not reported yet other 
statistics were available (observed events, expected events, variance), HR, standard 
error and 95% confidence intervals were calculated using various formulas provided by 
Hackshaw 200914 and the GraphPad Software Statistics Guide15.     
Other dichotomous outcomes including DRS, LRR and DM were expressed as risk 
ratios (RR) together with 95% confidence intervals based on the availability of data from 
these endpoints.  A p value of < 0.05 indicated a significant result for all outcomes 
measured.    
Data analysis was performed using STAT/SE ®, version 11 [Stat Crop., College Station, 
TX, USA].  Heterogeneity was evaluated based on the I2 statistic percentage or p-value 
(p< 0.05 indicates significant heterogeneity) to evaluate whether variability in results 
were attributed to heterogeneity rather than by sampling error.   
If heterogeneity was not significant, the Fixed-Effects Model of Mantel and Hanszel with 
the assumption all trials shared a common effect size would be used.  
RESULTS  
Selection of trials  
From the database query, 2021 reports were organized into a bibliographic database 
(Figure 1).  After removing duplicate articles, 1876 articles were excluded based on 
assessing the title and abstract. The remaining 145 texts were appraised by full-text.  
OSCC data published by the MACH-NC Collaborative Group from a meta-analysis 
performed by Blanchard et al7 were also included.    
Description of included studies and data analysis 
31 RCTs conducted from 1974 to 2015 were initially included. After systematic review, 
four trials were excluded.  One study16 had high overall bias risk, one did not state 
whether randomization was performed17 and two trials from Blanchard’s7 meta-analysis 
had no abstract to verify the study data since they were unpublished trials.  22 RCTs 
included were from the published meta-analysis by the MACH-NC Collaborative Group7.   
Five trials were further identified from the literature search and had data extracted 
directly from the article.   27 trials were included in the meta-analysis.     
Nine studies originated from establishments in France, six from the United States of 
America, three from Italy, and one each from Australia, Argentina, Brazil, Sweden, 
Germany Japan, China, India, and Thailand.  The earliest trial started recruitment in 
196518 whilst the most recent completed recruitment in 200819.   1484 participants were 
pooled in the ICT group whereas the control group had 1388 patients for the meta-
analysis.   14 RCTs compared the addition of ICT to surgery with/without radiotherapy20-
33,  10 against radiotherapy alone18,25,26,33-39, one for CCRT19, and one study40 did not 
specify the standard therapy given.  Regarding ICT regimen, twelve trials evaluated a 
Cisplatin-5-Fluorouracil containing protocol20,21,25,26,32,36-38,40-42, eight used a Cisplatin-
Bleomycin containing protocol22,24,28,33,34,36,38,39, two administered Bleomycin and 
Vinicristine23,27, one included Cisplatin, Bleomycin and 5-Fluorouracil (5-FU)38  and four 
had other ICT combinations18,29-31 where one trial used Cisplatin, 5-FU and Doxetaxel 
(TPF)30.  All trials had OS figures excluding one23.  Five trials reported data for 
DFS19,22,27,30,41, five for LRR19,23,27,30,41, and four for DM analysis19,27,30,41.  OS and DFS 
were reported from Zhong et al’s 2013 paper44 instead of the most recent 2015 article30 
since the 2015 paper did not provide enough data for OS analysis.    The shortest 
follow-up was at a median of 15 months19, whereas the longest follow-up period was a 
median of 11.5 years41.   Further descriptions of the trials included are available in the 
supplementary data, Table 1.       
 
Risk of Bias assessment 
Using the  Cochrane risk of bias assessment tool (Figure 2), 7 out of 27 
RCTs18,22,26,27,29,30,41 were considered low risk of bias.  However many studies had 
insufficient descriptions on how allocations into treatment groups during randomization 
was performed.  9 Trials20,21,23,25,32,37,39,42,43 had large proportions (at least three out of 
the five domains) of the risk assessment criteria categorized as unclear since 
insufficient information was provided for an analysis to be made.   
One trial16 had a high risk for bias and subsequently excluded from the analysis.  The 
symmetrical pattern in the funnel plot derived from the Begg’s test and calculations from 
the Egger’s test, suggested no evidence of publication bias (see supplementary data 
figure 1, 2, 3, 4).   
 
Overall Survival  
ICT provided no advantage compared to definitive treatment alone for OS (HR= 0.947, 
95% CI 0.85-1.05, p= 0.318).  Heterogeneity between these groups were not significant 
(I2: 32.3%, p= 0.059).   The cumulative meta-analysis plot shows the addition of ICT to 
locoregional treatment favours neither ICT nor definitive treatment for OS (Figure 3). 
Disease Free Survival   
There was no significant difference in DFS between patients treated with ICT and 
patients who only received definitive treatment (RR= 1.05, 95% CI 0.92-1.21, p= 0.462) 
(Figure 4). Heterogeneity between trials groups were not significant (I2 =0%, p= 0.556)  
Loco-regional recurrence  
There was a significant reduction in LRR (RR= 0.778, 95% CI 0.622-0.972, p= 0.027) 
amongst patients who treated with ICT compared those who only received definitive 
therapy (Figure 5).   Heterogeneity in these trials was not significant (I2= 11.3%, 
p=0.342).   When data from Luboinski et al23 was excluded in a sensitivity analysis, 
results were not significant (RR= 0.842, 95% CI 0.669-1.060, p= 0.143) and remained 
non-significant for heterogeneity (I2= 0%, p= 0.868) (Figure 6). 
Distant metastasis 
DM19,27,30,41 reduction was not significant between patients in the ICT and control group 
(RR= 0.626, CI 95% 0.361-1.086, p= 0.096) where heterogeneity between trials was not 
significant (I2 = 0%, p= 0.720) (Figure 7).    
Discussion 
Our paper is the first to include 27 RCTs over a 40-year period, investigating ICT on 
survival endpoints in a cumulative meta-analysis format.  The addition of ICT does not 
offer an improved OS for OSCC patients.  There was also no benefit to DFS, or DM 
using ICT, with the exception of a significant decrease in LRR for patients receiving ICT.     
There continues to be a lack of evidence supporting ICT for routine management in 
advanced OSCC patients.  Previous meta-analyses by Blanchard et al7 and Marta et al9 
found no advantage for OS in patients who had ICT added to their treatment.  Although 
we did not investigate OS based on clinical response to ICT, three studies24,30,41 
highlighted a correlation between a high clinical response to ICT and improved OS. 
Whilst it is difficult to ascertain whether the sensitivity was all attributed to chemotherapy, 
certain HNSCCs such as HPV-positive oropharyngeal cancers are associated with a 
better therapeutic response to chemo-radiation45.  This raises the possibility a select 
group of OSCCs, namely HPV-positive, are more sensitive to ICT.   While the role of 
HPV regarding treatment response and prognosis of OSCC is still controversial and 
inconclusive, a recent retrospective study demonstrated  an improved 2-year OS 
amongst HPV-positive OSCC patients compared to HPV-negative patients46. Therefore, 
clinical response and HPV status may be important factors contributing towards the 
success of ICT treatment in OSCC patients.  Future studies should investigate these 
subgroup of patients in correlation with OS to understand whether ICT can truly play a 
role in OSCC treatment. 
The significance observed in LRR reduction for ICT patients may need to be interpreted 
with caution.   When Luboinski et al’s 23 trial was excluded in the sensitivity analysis, the 
effect of ICT on LRR failed to achieve significance (p= 0.143).   It is important to note 
Luboinski et al23 only reported preliminary results where the trial also had multiple 
domains categorized as ‘unclear’ for bias risk.  Varying prognostic factors amongst the 
patient pools could have influenced the sensitivity analysis, and accounted for the 
unchanged OS despite LRR reduction between the experimental and control cohorts. 
Luboinski et al23 had more patients with T2 disease compared to other studies which 
had a greater number of patients with T3 and T4 disease.  Meanwhile, Richard et al27 
had more patients with T4 disease assigned to the ICT cohort whilst Bossi et al41 
reported a higher incidence of patient death from unknown causes or treatment toxicity.  
Despite an observed reduction in DM for patients who received ICT, our results only 
approached but never achieved significance (Figure 9).   Yet, since Ma et al8 
demonstrated a significant reduction for DM in HNSCC patients receiving TPF, future 
studies should further investigate this endpoint for a more conclusive result as our 
analysis only included 4 trials.   
In our meta-analysis, a taxane regimen did not seem to benefit OS considering a shift 
favoring LRT alone from the forest plot (Figure 3) was observed when a study30 with 
TPF was included.   Meta-analyses by Zhang et al12 and Kim et al47 showed ICT using 
TPF did not improve OS for HNCC patients, with adverse events cited as a possible risk 
for increased morbidity and mortality12,47.  However, it is too soon to discredit TPF, 
considering we only included one trial.   Kim et al found a significant improvement in OS 
and PFS for non-oropharyngeal head and neck cancer patients who had received TPF 
treatment47.  Given oral cancer was the second most prevalent HNSCC subtype 
included in 3 of the 6 studies within Kim et al’s meta-analysis, perhaps ICT using TPF 
may provide a breakthrough for OSCC survival.   More studies are required to conclude 
whether TPF has a future role for increasing OSCC survival rates.   
A cumulative meta-analysis is frequently criticized for potentially replicating and 
amplifying biases.  Yet, a cumulative and a conventional meta-analysis will present 
identical results since they are using the same metrics and statistical model.  Hence, 
heterogeneity and the quality of studies will affect both types of analysis equally.    A 
cumulative meta-analysis is reliable for presenting evidence from multiple trials 
conducted over an extended period of time and should be considered in use with a 
conventional meta-analyses.    As demonstrated in our study, it can aid identifying when 
and if an intervention ever reaches significance whilst summarizing trends (or the lack 
of). To tackle concerns about incorporating bias and poor quality studies that would 
skew the analysis outcomes, systematic reviews should be carried out in conjunction to 
minimize these risks.   
Conclusion 
ICT has never provided an improvement to OS for OSCC patients, which can be 
effectively visualized through a cumulative meta-analysis approach.  Although our 
analysis is the first to demonstrate a statistically significant reduction in LRR amongst 
patients who received ICT, indicating ICT is possibly effective in managing microscopic 
disease, these results should also be interpreted with caution. 
 
Figure Legends 
Figure 1:  A Flow Chart of Literature Search Methods  
Figure 2: Risk of Bias Assessment for Trials Identified in the Literature Search 
Figure 3: OS between the ICT group and patients who only received definitive therapy 
Figure 4: DFS between the ICT group and patients who only received definitive therapy 
Figure 5: LRO between the ICT group and patients who only received definitive therapy 
Figure 6: A sensitivity analysis of LRO between the ICT group and patients who only 
received definitive therapy  
Figure 7: DM between the ICT group and patients who only received definitive therapy  
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